Y-mAbs
is a New York-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer... Read moreY-mAbs
is a New York-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer... Read more
News
Aug 08, 2025
Owler
Y-mAbs Therapeutics, Inc.: Y-mAbs's revenue changed from $88.66M in Mar 2025 to $85.39M in Jun 2025
Aug 07, 2025
Benzinga
Y-mAbs: Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
May 27, 2025
Yahoo
Y-mAbs: Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
May 27, 2025
StreetInsider
Press Release: Y-mAbs : Advocacy-led Consensus Sets Path to Better High-Risk Neuroblastoma Care
May 13, 2025
Owler
Y-mAbs Therapeutics, Inc.: Y-mAbs's revenue changed from $87.69M in Dec 2024 to $88.66M in Mar 2025
May 13, 2025
Benzinga
Y-mAbs: Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
May 07, 2025
StreetInsider
Press Release: Y-mAbs : Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA)
Apr 27, 2025
Nasdaq
Y-mAbs: Y-mAbs Therapeutics Presents Preclinical Data on CD38-SADA at 2025 AACR Annual Meeting
Apr 25, 2025
FinanzNachrichten
Y-mAbs: Y-mAbs Therapeutics, Inc.: Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
Mar 05, 2025
Owler
Y-mAbs Therapeutics, Inc.: Y-mAbs's employee count changed from 100 in Dec 2023 to 107 in Dec 2024
Y-mAbs Competitors
1
2
3
4
5
6
7
8
9
10